This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechs: Archive
Should You Buy AbbVie Stock Ahead of Q3 Earnings Report?
by Sundeep Ganoria
ABBV's Q3 results are likely to hinge on Skyrizi and Rinvoq growth, as Humira erosion and hefty IPR&D charges are expected to pressure near-term earnings.
RHHBYNegative Net Change JNJNegative Net Change ABBVNegative Net Change
biotechs earnings-preview medical pharmaceuticals
Is Halozyme Stock a Portfolio Must-Have Ahead of Q3 Earnings?
by Kanishka Das
HALO gears up for third-quarter earnings with strong royalty growth and a new acquisition poised to shape its 2025 outlook.
RHHBYNegative Net Change JNJNegative Net Change HALOPositive Net Change
biotechs
ANI Pharmaceuticals to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
ANIP's rising Cortrophin Gel sales and new rare disease products, along with generic and other segments, could power another earnings beat this quarter.
ALNYPositive Net Change INCYPositive Net Change ANIPNegative Net Change EXASPositive Net Change
biotechs
Dr. Reddy's Q2 Earnings Beat Estimates, Generics Sales Boost Revenues
by Zacks Equity Research
RDY posts a Q2 earnings and revenue beat as global generics drive growth, while new launches and biosimilar advances shape its pipeline.
RDYNegative Net Change MRKNegative Net Change AMGNPositive Net Change ALVONegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
by Ahan Chakraborty
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
BMYPositive Net Change MRKNegative Net Change LLYPositive Net Change GILDPositive Net Change ABBVNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?
by Zacks Equity Research
Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.
BMYPositive Net Change PFEPositive Net Change BNTXNegative Net Change
biotechnology biotechs earnings medical pharmaceuticals
NVO vs. GPCR: Which Obesity Stock is the Better Buy Right Now?
by Sundeep Ganoria
Novo Nordisk faces headwinds and leadership shifts, while Structure Therapeutics eyes pivotal obesity-drug data later this year.
NVONegative Net Change LLYPositive Net Change GPCRPositive Net Change
biotechs medical pharmaceuticals
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now?
by Ekta Bagri
Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength
BMYPositive Net Change PFEPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte Gears Up to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
INCY eyes strong Q3 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.
NVSPositive Net Change LLYPositive Net Change INCYPositive Net Change EXASPositive Net Change
biotechnology biotechs earnings medical pharmaceuticals
REGN Q3 Earnings: Will Higher Dupixent Profits Offset Eylea Sales Decline?
by Zacks Equity Research
Regeneron's Q3 earnings on Oct. 28 will likely spotlight Dupixent profits and strong Eylea HD uptake amid lingering Eylea competition.
REGNNegative Net Change ALNYPositive Net Change NVSPositive Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Here's How Eli Lilly's Oncology Drugs Are Poised Ahead of Q3 Earnings
by Sundeep Ganoria
LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.
AZNPositive Net Change PFEPositive Net Change MRKNegative Net Change LLYPositive Net Change
biotechs medical pharmaceuticals
Viking Therapeutics Posts Wider-Than-Expected Loss in Q3, Sales Nil
by Zacks Equity Research
VKTX posts a wider Q3 loss and no sales, as R&D costs surge and obesity drug studies drive spending higher.
ALNYPositive Net Change ALKSNegative Net Change VKTXNegative Net Change HOWLNegative Net Change
biotechs earnings medical
ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition
by Zacks Equity Research
Alkermes inks $2.1B deal to acquire Avadel, adding the latter's Lumryz and new growth potential to its portfolio.
ALKSNegative Net Change AVDLPositive Net Change CSTLPositive Net Change CMMBPositive Net Change
biotechs
Will Higher Royalties From Partners Fuel HALO's Growth in H2 2025?
by Kanishka Das
Halozyme boosts its 2025 revenue outlook on surging royalties from Darzalex SC, Phesgo and Vyvgart Hytrulo, though partner reliance persists.
RHHBYNegative Net Change JNJNegative Net Change HALOPositive Net Change
biotechs
How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q3 Results?
by Ahan Chakraborty
Novo Nordisk's Q3 results hinge on Ozempic and Wegovy sales as demand growth slows amid rivalry, market limits and compounded drug headwinds.
NVONegative Net Change LLYPositive Net Change VKTXNegative Net Change
biotechnology biotechs medical pharmaceuticals
NVO Stock Falls Amid Governance Shift as Foundation Seeks New Board
by Zacks Equity Research
Novo Nordisk stock slides as the Novo Nordisk Foundation pushes a sweeping board overhaul, signaling a new era in governance and strategic direction.
ALNYPositive Net Change NVONegative Net Change LLYPositive Net Change ANIPNegative Net Change
biotechnology biotechs medical pharmaceuticals
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
by Ekta Bagri
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
BDTXPositive Net Change ORICNegative Net Change
biotechnology biotechs medical pharmaceuticals
SMMT's Q3 Loss Wider Than Expected, Stock Down on Study Amendments
by Zacks Equity Research
Summit Therapeutics posts a wider Q3 loss as costs surge and investors react to protocol changes in a key ivonescimab study.
MRKNegative Net Change SMMTPositive Net Change ONCPositive Net Change
biotechs earnings medical
Best Momentum Stocks to Buy for Oct. 21
by Zacks Equity Research
VSTM, AS and SOTK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on Oct. 21, 2025.
VSTMPositive Net Change SOTKNegative Net Change ASNegative Net Change
biotechs
Roche's Gazyva Secures FDA Nod for Label Expansion in Lupus Nephritis
by Zacks Equity Research
RHHBY secures FDA approval to expand Gazyva's label for treating lupus nephritis, offering patients a faster and more convenient treatment option.
ALNYPositive Net Change RHHBYNegative Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
NVO's Rybelsus Gets FDA Nod to Reduce Heart Risk in Diabetes Patients
by Zacks Equity Research
Novo Nordisk secures FDA approval for Rybelsus as the first oral GLP-1 therapy proven to cut major heart risks in adults with type II diabetes.
ALNYPositive Net Change NVONegative Net Change ANIPNegative Net Change CMMBPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 Stocks With Recent Price Strength to Maximize Your Gains
by Nalak Das
FLUX, AUGO, ARCT and STRL are showing notable price strength amid a volatile market.
ARCTPositive Net Change STRLNegative Net Change FLUXNegative Net Change AUGOPositive Net Change
basic-materials biotechs construction tech-stocks
Will BMY's Growth Portfolio Drive Third-Quarter Results?
by Ekta Bagri
Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.
BMYPositive Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
New Strong Buy Stocks for Oct. 21: NEM, AS and More
by Zacks Equity Research
NEM, RY, AS, VSTM and SOTK have been added to the Zacks Rank #1 (Strong Buy) List on Oct. 21, 2025.
NEMNegative Net Change RYPositive Net Change VSTMPositive Net Change SOTKNegative Net Change ASNegative Net Change
biotechs finance
How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results?
by Ahan Chakraborty
CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.
PFEPositive Net Change AMPHPositive Net Change CRMDNegative Net Change
biotechnology biotechs medical pharmaceuticals